Evaluation of serum pentraxin–3 (PTX–3) levels in cats with neoplasia

• Nihan Avci Aksaray University, Faculty of Veterinary Medicine, Department of Surgery. Aksaray, Türkiye. https://orcid.org/0000-0001-6789-8474
• Melek Aydemir Aksaray University, Faculty of Veterinary Medicine, Department of Internal Medicine. Aksaray, Türkiye. https://orcid.org/0000-0002-4732-8279
• Fehmiye Gumus-Ozdil Aksaray University, Faculty of Veterinary Medicine, Department of Surgery. Aksaray, Türkiye. https://orcid.org/0000-0003-1670-0709
• Orhan Yavuz Dokuz Eylul University, Faculty of Veterinary Medicine, Department of Pathology. İzmir, Türkiye. https://orcid.org/0000-0002-8075-9564
• Hidayet Metin Erdogan Aksaray University, Faculty of Veterinary Medicine, Department of Internal Medicine. Aksaray, Türkiye. https://orcid.org/0000-0003-1261-4352

DOI: https://doi.org/10.52973/rcfcv-e362820

Keywords: Feline injection-site sarcoma, Pentraxin–3, biomarker, fibrosarcoma, pleomorphic sarcoma

Abstract

Pentraxin–3 is a multifunctional protein implicated in human oncology due to its roles in regulating inflammation, angiogenesis, and tumor progression. However, its potential as a biomarker in feline oncology remains insufficiently investigated. This study evaluated serum Pentraxin–3 levels in cats with feline injection-site sarcoma and their association with histopathological features. A cohort of 14 cats was included, comprising seven clinically healthy controls and seven with subcutaneous sarcomas. Histopathological examination identified fibrosarcoma (n = 3) and pleomorphic sarcoma (n = 4). Cats with fibrosarcoma were generally characterized by smaller, well-demarcated lesions (< 6 cm), with serum Pentraxin–3 levels ranging from 31 to 89 ng·mL–1. In contrast, cases of pleomorphic sarcoma exhibited infiltrative, poorly defined tumors and significantly higher Pentraxin–3 levels (90–530 ng·mL–1). These findings suggest that serum Pentraxin–3 may reflect tumor burden, histopathological subtype, and biological aggressiveness in feline injection-site sarcoma. However, due to the limited sample size, larger-scale studies are necessary to confirm this association.

References

Arslanoğlu MÖ. Yenidoğan solunum sistemi hastalıklarında pentraksin III (PTX3) düzeyleri [Pentraxin III (PTX3) levels in newborn respiratory disorders]. [master’s thesis on the Internet]. Eskişehir (Türkiye): Eskişehir Osmangazi University; 2012 [cited 7 Oct 2025]; 74 p. Turkish. Available in: https://goo.su/Ymxjn

Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, Mantovani. A. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J. Hepatol. [Internet]. 2016; 64(6):1416–1427. doi: https://doi.org/f8mr9m DOI: https://doi.org/10.1016/j.jhep.2016.02.029

Zlibut A, Bocsan IC, Agoston-Coldea L. Pentraxin–3 and endothelial dysfunction. Adv. Clin. Chem. [Internet]. 2019; 91:163–179. doi: https://doi.org/qq8t

Scuderi SA, Ardizzone A, Salako AE, Pantò G, De Luca F, Esposito E, Capra AP. Pentraxin 3: A main driver of inflammation and immune system dysfunction in the tumor microenvironment of glioblastoma. Cancers [Internet]. 2024; 16(9):1637. doi: https://doi.org/qq8v DOI: https://doi.org/10.3390/cancers16091637

Taşçene N. Akut Faz Proteinlerinin Hayvanlarda Önemi [Importance of acute phase proteins in animals] Lalahan Hayv. Araşt. Enst. Derg. [Internet]. 2017 [cited 7 Oct 2025]; 57(1):52–60. Turkish. Available in: https://goo.su/wioRV

Doddy FD, Glickman LT, Glickman NW, Janovitz EB. Feline fibrosarcomas at vaccination sites and non-vaccination sites. J. Comp. Pathol. [Internet]. 1996; 114(2):165–174. doi: https://doi.org/cpkt5j DOI: https://doi.org/10.1016/S0021-9975(96)80005-3

Couto SS, Griffey SM, Duarte PC, Madewell BR. Feline vaccine- associated fibrosarcoma: morphologic distinctions. Vet. Pathol. [Internet]. 2002; 39(1):33–41. doi: https://doi.org/d34m3m DOI: https://doi.org/10.1354/vp.39-1-33

Hartmann K, Egberink H, Möstl K, Addie DD, Belák S, Boucraut- Baralon C, Frymus T, Lloret A, Hofmann-Lehmann R, Marsilio F, Pennisi MG, Tasker S, Thiry E, Truyen U, Hosie MJ. Feline injection-site sarcoma and other adverse reactions to vaccination in cats. Viruses [Internet]. 2023; 15(8):1708. doi: https://doi.org/gsqthb DOI: https://doi.org/10.3390/v15081708

Hartmann K, Day MJ, Thiry E, Lloret A, Frymus T, Addie D, Boucraut-Baralon C, Egberink H, Gruffydd-Jones T, Horzinek, MC, Hosie MJ, Lutz H, Marsilio F, Pennisi MG, Radford AD, Truyen U, Möstl K. Feline injection-site sarcoma: ABCD guidelines on prevention and management. J. Feline Med. Surg. [Internet]. 2015; 17(7):606–613. doi: https://doi.org/gg3j72 DOI: https://doi.org/10.1177/1098612X15588451

Saba CF. Vaccine-associated feline sarcoma: Current perspectives. Vet. Med. (Auckl). [Internet]. 2017; 8:13–20. doi: https://doi.org/qq8z DOI: https://doi.org/10.2147/VMRR.S116556

Srivastav A, Kass PH, McGill LD, Farver TB, Kent MS. Comparative vaccine-specific and other injectable risk factors for injection- site sarcomas in cats. J. Am. Vet. Med. Assoc. [Internet]. 2012; 241(5):595–602. doi: https://doi.org/gnnbgw DOI: https://doi.org/10.2460/javma.241.5.595

Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: From C-reactive protein to the long pentraxin PTX3. J. Clin. Immunol. [Internet]. 2008; 28:1–13. doi: https://doi.org/b9s5m6 DOI: https://doi.org/10.1007/s10875-007-9126-7

Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C, Mantovani A. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell [Internet]. 2015; 160(4):700– 714. doi: https://doi.org/f6x5sr DOI: https://doi.org/10.1016/j.cell.2015.01.004

Doni A, Stravalaci M, Inforzato A, Magrini E, Mantovani A, Garlanda C, Bottazzi B. The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer. Front. Immunol. [Internet]. 2019; 10:712. doi: https://doi.org/gm9sdt DOI: https://doi.org/10.3389/fimmu.2019.00712

Luna LG. Manual of histologic staining methods of the Armed Forces Institute of Pathology. 3rd ed. New York (USA): McGraw- Hill; 1968.

Meuten DJ. Tumors in domestic animals. 5th ed. Ames (Iowa, USA): Wiley-Blackwell; 2017. DOI: https://doi.org/10.1002/9781119181200

Haas JV. Klinik, Labordiagnostik und verwendete Impfstoffe bei Katzen mit einem Fibrosarkom – Eine Übersicht über die Patienten der Medizinischen Kleintierklinik 1999 – 2007 [Clinical presentation, laboratory diagnostics, and vaccines used in cats with fibrosarcoma – An overview of patients at the Small Animal Clinic 1999 – 2007]. [dissertation on the Internet]. Munich (Germany): Ludwig Maximilian University of Munich; 2009 [cited 7 Oct 2025]; 99 p. German. Available in: https://goo.su/j5wk

Çalışkan M, Tenekeci GY. Kedi Enjeksiyon İlişkili Sarkomalar: 18 Kedide Cerrahi Sonuçlar [Feline vaccine-associated sarcomas: surgical results in 18 cats]. Vet. Hekim. Der. Derg. [Internet]. 2019; 90(1):22–29. Turkish. doi: https://doi.org/qq83 DOI: https://doi.org/10.33188/vetheder.483641

Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin–3 is a novel biomarker of lung carcinoma. Clin. Cancer Res. [Internet]. 2011; 17(8):2395–2399. doi: https://doi.org/bkbc2w DOI: https://doi.org/10.1158/1078-0432.CCR-10-3024

Zhang D, Ren WH, Gao Y, Wang NY, Wu WJ. Clinical significance and prognostic value of pentraxin–3 as serologic biomarker for lung cancer. Asian Pac. J. Cancer Prev. [Internet]. 2013; 14(7):4215–4221. doi: https://doi.org/f5d2x5 DOI: https://doi.org/10.7314/APJCP.2013.14.7.4215

Choi B, Lee EJ, Song DH, Yoon SC, Chung YH, Jang Y, Kim SM, Song Y, Kang SW, Yoon SY, Chang EJ. Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. Oncotarget [Internet]. 2014; 5(2):481–492. doi: https://doi.org/f52424 DOI: https://doi.org/10.18632/oncotarget.1664

Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the cardiovascular health study. Arterioscler. Thromb. Vasc. Biol. [Internet]. 2009; 29(4):594–599. doi: https://doi.org/dv48z3 DOI: https://doi.org/10.1161/ATVBAHA.108.178947

Owczarek AJ, Ochman A, Chudek A, Mossakowska M, Puzianowska-Kuźnicka M, Kujawska-Danecka H, Zdrojewski T, Więcek A, Chudek J, Olszanecka-Glinianowicz M. Pentraxin–3 and C-reactive protein plasma levels predict survival in older adults with or without metabolic syndrome – results of the PolSenior2 substudy. Immun. Ageing. [Internet]. 2025; 22(1):16. doi: https://doi.org/qq84 DOI: https://doi.org/10.1186/s12979-025-00509-9

Aygün O, Yıldız R. Evaluation of thrombomodulin and pentraxin–3 as diagnostic biomarkers in calves with sepsis. Vet. Med. [Internet]. 2018; 63(7):313–320. doi: https://doi.org/gdx69p DOI: https://doi.org/10.17221/159/2017-VETMED

Aydemir M. Kolostral pentraksin–3 düzeyinin neonatal buzağı sağlığı ve pasif transfer immünite ile ilişkisinin araştırılması [Investigation of the relationship of colostral pentraxin–3 level with neonatal calf health and passive transfer immunity] [dissertation on the Internet]. Aksaray (Türkiye): Aksaray University; 2025 [cited 7 Oct 2025]. 149 p. Turkish. Available in: https://goo.su/6cGd1Bw

Akyüz E, Merhan O, Aydın U, Sezer M, Atlı K, Büyük E, Batı YU, Saltık HS, Tanrıverdi E, Çelebi Ö, Kuru M, Cihan M, Otlu S, Gökce G. Pentraxin–3, endothelin–1, some biochemical parameters and hematology in bovine respiratory disease complex. Iran J. Vet. Res. [Internet]. 2023; 24(2):143–150. doi: https://doi.org/qq86

Liu B, Zhao Y, Guo L. Increased serum pentraxin–3 level predicts poor prognosis in patients with colorectal cancer after curative surgery: a cohort study. Medicine [Internet]. 2018; 97(40):e11780. doi: https://doi.org/qq88 DOI: https://doi.org/10.1097/MD.0000000000011780

Zhou S, Li N, Haishaer D, Zhao H. PTX3 as a diagnostic and prognostic biomarker in lung adenocarcinoma: a comprehensive analysis. Discov. Oncol. [Internet]. 2025; 16(1):1158. doi: https://doi.org/qq89 DOI: https://doi.org/10.1007/s12672-025-02983-5

Infante M, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, Roncalli M, Cavuto S, Pesce S, Monari M, Valaperta S, Montanelli A, Solomon D, Bottoni E, Errico V, Voulaz E, Bossi M, Chiesa G, Passera E, Mantovani A, Alloisio M. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. Int. J. Cancer [Internet]. 2016; 138(4):983–991. doi: https://doi.org/qq9d DOI: https://doi.org/10.1002/ijc.29822

Presta M, Foglio E, Churruca-Schuind A, Ronca R. Long pentraxin–3 modulates the angiogenic activity of fibroblast growth factor–2. Front. Immunol. [Internet]. 2018; 9:2327. doi: https://doi.org/gfg9xb DOI: https://doi.org/10.3389/fimmu.2018.02327

Ronca R, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, Matarazzo S, Rezzola S, Maiolo D, Torella R, Morani E, Mazzieri R, Escobar G, Mor M, Colombo G, Presta M. Long- pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell [Internet]. 2015; 28(2):225–239. doi: https://doi.org/qq9p DOI: https://doi.org/10.1016/j.ccell.2015.07.002

Cecco BS, Henker LC, De Lorenzo C, Schwertz CI, Bianchi RM, Da Costa FVA, Driemeier D, Pavarini SP, Sonne L. Epidemiological and pathological characterization of feline injection site sarcomas in southern Brazil. J. Comp. Pathol. [Internet]. 2019; 172:31–36. doi: https://doi.org/qq9c DOI: https://doi.org/10.1016/j.jcpa.2019.08.009